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A Genetic Epidemiologic Study of Candidate Genes
Involved in the Optic Nerve Head Morphology
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Andre G. Uitterlinden,1,8 Ben A. Oostra,9 Hans G. Lemij,4 Caroline C. W. Klaver,1,3
Nomdo M. Jansonius,1,10 Johannes R. Vingerling,1,3 and Cornelia M. van Duijn1
PURPOSE. The size of the optic nerve head, referred to as disc
area (DA), and the vertical cup-disc ratio (VCDR), are clinically
relevant parameters for glaucomatous optic neuropathy. Al-
though these measures have a high heritability, little is known
about the underlying genes. Previously, the genes SALL1 and
SIX1 were found to be genome-wide significantly associated
with DA and VCDR. The purpose of the present study was to
investigate whether genes encoding protein known to interact
with protein encoded by SALL1 and SIX1 are also associated
with either DA or VCDR.
METHODS. A total of 38 candidate genes were chosen covering
all known proteins interacting with SALL1 and SIX1. These
were initially studied in the Rotterdam Study (RS)-I, including
5312 Caucasian subjects characterized for DA and VCDR. Pos-
itive findings were further investigated in two independent
cohorts (RS-II and RS-III) and finally replicated in a fourth
population (ERF). Bonferroni correction was applied to the
meta-analyses.
RESULTS. Three loci were found to be associated with DA. The
only locus significant after correcting for multiple testing is
located on chromosome 11p13. Three single nucleotide poly-
morphisms (SNPs) in ELP4, a gene which neighbors and plays
a crucial role in the expression of PAX6, show association in
meta-analysis of the four cohorts yielding P values of respec-
tively 4.79  106, 3.92  106, and 4.88  106 which is
below the threshold dictated by the most conservative Bonfer-
roni correction (P  5.2  106).
CONCLUSIONS. This study suggests that the ELP4-PAX6 region
plays a role in the DA. Further research to confirm this finding
is needed. (Invest Ophthalmol Vis Sci. 2012;53:1485–1491)
DOI:10.1167/iovs.11-7384
One of the major clinical markers associated with the de-velopment of glaucomatous optic neuropathy is the ver-
tical cup-disc ratio (VCDR), which is a quantitative measure for
the size of the optic cup relative to the optic disc size (disc
area; DA).1 Enlargement of the optic cup is a diagnostic sign of
primary open-angle glaucoma (POAG), a leading cause of visual
field loss and blindness worldwide.2 VCDR has been shown to
be the most useful clinical sign in the diagnosis of glaucoma;
the cup most commonly enlarges vertically in POAG.1 While
the nature of the relationship of DA to POAG has been a
subject of debate, VCDR is associated with DA. In that realm,
DA has been studied as an endophenotype for POAG and other
disorders.3 Both DA and VCDR are known to be highly herita-
ble (52%–59%),4,5 and the genes involved in DA are just begin-
ning to be discovered. Previously, we performed a genome-
wide association study and found several genes associated with
optic disc parameters, including sal-like 1 (SALL1; chromo-
some 16q12.1) with DA and sine oculis homeobox homolog 1
(SIX1; chromosome 14q22–23) with VCDR.3 Recently, the
latter gene has also been associated with open-angle glau-
coma.6 SALL1 encodes a zinc finger transcriptional repressor
involved in organogenesis and may be linked to POAG through
its interaction with SIX1.7 SIX1 is a transcription factor known
to activate SALL1 in kidney development.7 Transcription from
the SALL1 promoter has been shown to be strikingly activated
by the SIX1 protein.7 While the Drosophila Six homolog is
known to interact within a network of genes including eyeless,
eyes absent, and dachshund to induce compound eye organo-
genesis, Six1 is not expressed in the developing mouse eye.8
However, the optix subclass of Six genes, comprising Six3 and
Six6, may play a role in the vertebrate eye.8 SIX1 and SALL1
operate within a regulatory complex. Investigations of genes
that operate within this complex may reveal the connections
between the protein pathways implicated in DA, VCDR, and
glaucomatous pathology.
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In the present study we aimed to investigate whether the
genes that encode proteins known to interact with the Sall1
and Six1 proteins are associated with either DA or VCDR to
further elucidate the operational pathways. For this purpose
we tested 38 candidate genes encoding proteins interacting
with the proteins encoded by SIX1 and SALL1 and assessed
their association with DA and/or VCDR in the Rotterdam




This study was conducted in four cohorts from the Netherlands, the
Rotterdam Study (RS)-I, RS-II, RS-III, and the Erasmus Rucphen family
study (ERF). RS-I is the discovery cohort and a prospective population-
based cohort study of 7983 residents aged 55 years and older living in
Ommoord, a district of Rotterdam, the Netherlands.9 Baseline exami-
nation for the ophthalmic part took place between 1991 and 1993;
follow-up examinations were performed from 1997 to 1999 and from
2002 to 2006.
The RS-II prospective population-based cohort study comprised
3011 residents aged 55 years and older from the same district of
Rotterdam while similarly the RS-III study included 3932 residents, but
aged 45 years and older. The rationale and study designs of these
cohorts were similar to that of the RS-I.9 The baseline examination of
RS-II took place between 2000 and 2002; follow-up examination was
performed from 2004 to 2005. Baseline examination of RS-III took
place between 2006 and 2009.
In RS-I, of 5974 participants who were genotyped, 5107 had reli-
able baseline optic disc data and another 205 had reliable follow-up
disc data resulting in a total of 5312 included participants. From RS-II
a total of 2048 out of 2157 genotyped participants were included in the
study, of which 90 were based on follow-up data. From RS-III a total of
1966 genotyped participants were included, resulting in a total of 9326
participants.
Finally, the fourth cohort was ERF, now consisting of 1919 geno-
typed participants. This is a family-based study of several thousand
individuals from a genetic isolate in the southwest of the Netherlands,
founded in the mid-18th century by some 150 individuals.10 Data
collection began in June 2002 and finished in February 2005.
All measurements in these studies were conducted after the Med-
ical Ethics Committee of the Erasmus University Rotterdam had ap-
proved the study protocols and all participants had given their written
informed consent in accordance with the Declaration of Helsinki.
Ophthalmic Examination
In RS-I and RS-II digitized stereoscopic imaging of the optic disc was
used for the assessment of the optic nerve head (Topcon ImageNet
System; Topcon Corporation, Tokyo, Japan), while RS-III and ERF used
confocal scanning laser ophthalmoscopy (Heidelberg Retina Tomo-
graph [HRT]; Heidelberg Engineering, Dossenheim, Germany).3 It has
been shown that both instruments are comparable and that there is
high correlation for all stereometric parameters.11
To determine DA and VCDR with the stereoscopic imaging system
(ImageNet System) used for the RS-I and RS-II populations, two trained
technicians marked points on the disc margin and near the retinal
blood vessels which were used by the stereoscopic imaging system
(ImageNet System) to outline the disc margin. The stereoscopic imag-
ing system (ImageNet System) systematically measures a larger DA than
HRT. In brief, the mean difference of agreement between HRT and the
stereoscopic imaging system (ImageNet System) is 0.05; 95% confi-
dence interval (CI) of the difference is 0.07 to 0.03; limits of
agreements 0.25 to 0.16. When measured with both methods there
is a systematic difference in DA.11
Genotyping and Imputations
Genomic DNA was extracted from whole blood samples using stan-
dard methods.12 Genome-wide single nucleotide polymorphism (SNP)
genotyping was performed using an assay (Infinium II; Illumina, Inc.,
San Diego, CA) on a microarray (HumanHap 550 Genotyping Bead
Chips; Illumina Inc). Approximately 2 million SNPs were imputed
using release 22 HapMap CEU population (www.hapmap.org) as ref-
erence. The imputations were performed using MACH software
(http://www.sph.umich.edu/csg/abecasis/MACH/). The quality of im-
putations was checked by contracting imputed and actual genotypes at
78,844 SNPs not present on an array (Illumina 550K; Illumina, Inc.) in
437 individuals for whom these SNPs were directly typed using an
array set (Affymetrix 500K; SeqWright, Inc., Houston, TX). Using the
“best guess” genotype for imputed SNPs the concordance rate was 99%
for SNPs with R2 (ratio of the variance of imputed genotypes to the
binomial variance) quality measure greater than 0.9; concordance was
still high (94%) when R2 was between 0.5 and 0.9. For imputed SNPs
we chose an R2 value of 0.85 as the minimum for consideration.
Choice of Candidate Genes
We constructed a list of interacting proteins for SALL1 and SIX1 using
internet databases (GeneCards; www.genecards.org). Because SIX3
and SIX6 are expressed during development of the human eye and
SIX4 and SIX5 also play a role in the eye,8 we decided to include all the
SIX genes in our analysis. Table 1 provides an overview of the candi-
date genes investigated in this study. Of note is the overlap of the
regions enframing SIX3 and SIX2 on chromosome 2 and SIX6, SIX1
and SIX4 on chromosome 14.
To determine gene positions we used NCBI build version 36.3
(ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/ARCHIVE/BUILD.36.3/
mapview/seq_gene.md.gz). We extracted SNPs within a region of
interest comprising 100 kb on each side of the 38 candidate genes
to be certain we included the promoter regions. Only SNPs with
P  0.0001 for Hardy-Weinberg equilibrium test and with genotype
call rate  95% were included. A total of 9611 SNPs met these
criteria and were selected for the association test.
Statistical Analysis
All analyses were performed using R statistical package (version 2.10.0
for Linux; www.r-project.org). Allele-based linear regression methods
were used to test for association between a single SNP and the traits
using ProbABEL (version 0.2.0-beta).13 Betas and their standard errors
for each SNP were derived adjusting for age and sex in the analyses of
DA, and additionally adjusted for DA in the analyses of VCDR. All genes
with nominal significant results in RS-I were followed up in the RS-II
and RS-III cohorts in a meta-analysis using MetABEL R package (version
0.0-3).14 For each candidate gene we calculated the P value signifi-
cance threshold (p-sig) according to Bonferroni by adjusting for the
number of SNPs tested within the respective region. After the meta-
analysis in the three Rotterdam Study cohorts, the top SNPs were then
followed up in another independent cohort, ERF. Finally we performed
a meta-analysis in all four cohorts using the MetABEL R package. We
used two different cutoffs for significance: Bonferroni adjustment for
the number of SNPs sent for replication (P  0.05/6  8.33  103);
and the more conservative Bonferroni adjustment on all SNPs tested in
the discovery cohort (P  0.05/9611  5.20  106).
RESULTS
The general characteristics of the study populations are shown
in Table 2. Participants of RS-III and ERF were younger com-
pared with the other two cohorts. Slightly  50% of partici-
pants were female in all populations. Of note is that in RS-III
and ERF the mean DA and VCDR were smaller than in the other
two populations. This is due to the difference in equipment11
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and does not affect the results3 because all cohorts were
analyzed separately and later meta-analyzed.
Of the 38 investigated genes in our initial analysis in RS-I we
found 15 regions to be nominally significant (P  0.05) for DA
and 16 for VCDR (Table 1). Next we performed a meta-analysis
for these candidate genes including all three Rotterdam Study
cohorts. Four genes reached statistical significance for DA after
adjusting for multiple testing (based on the number of SNPs in
the gene). These were paired box 6 (PAX6), paired box 1
(PAX1), ephrin receptor tyrosine kinase A3 (EPHA3), and sine
oculis homeobox homolog 2 (SIX2) (data not shown). A single
SNP in the gene paired box 2 (PAX2) was significant for VCDR
(rs11190730). However, the SNP was discarded due to its low
imputation quality (R2  0.50).
To corroborate the association with DA found in the Rot-
terdam Study cohorts, we tested the six top SNPs—three from
PAX6 and one each from PAX1, EPHA3, and SIX2 each in a
fourth cohort, ERF. These data were combined with those of
the other three cohorts in a final meta-analysis (Table 3). When
adjusting for the number of SNPs selected for replication, five
of the six SNPs remained significant (rs953476 from gene
EPHA3 with a P-value of 0.02 was discarded), but when per-
TABLE 1. The 38 Genes/35 ROIs for Association with the Traits DA and VCDR
Gene Chr Start Gene* End Gene* Start Region End Region ROI SNPs (n) DA† VCDR†
EYA3 1 28300819 28415131 28200819 28515131 EYA3 150
CTBS 1 85018804 85040163 84918804 85140163 CTBS 273 Y Y
MYOG 1 203052257 203055377 202952257 203155377 MYOG 230 Y
SIX3 2 45169037 45172390 45069037 45272390 SIX32 358 Y
SIX2 2 45232324 45236542 45132324 45336542 SIX32
HOXD13 2 176957532 176960666 176857532 177060666 HOXD13 134
EPHA4 2 222282747 222437010 222182747 222537010 EPHA4 281
PAX3 2 223064607 223163700 222964607 223263700 PAX3 282 Y
EPHA3 3 89156674 89531284 89056674 89631284 EPHA3 457 Y
MDFI 6 41606195 41621982 41506195 41721982 MDFI 150 Y
TAF8 6 42018251 42048644 41918251 42148644 TAF8 138 Y
EYA4 6 133562495 133853258 133462495 133953258 EYA4 586 Y
EZR 6 159186773 159240456 159086773 159340456 EZR 262
HOXA13 7 27236499 27239725 27136499 27339725 HOXA13 326
SHH 7 155595558 155604967 155495558 155704967 SHH 299 Y
MNX1 7 156797547 156803347 156697547 156903347 MNX1 151 Y
EYA1 8 72109668 72274467 72009668 72374467 EYA1 500 Y Y
TERF1 8 73921097 73959987 73821097 74059987 TERF1 382
TG 8 133879205 134147143 133779205 134247143 TG 746 Y Y
PAX2 10 102505468 102589695 102405468 102689695 PAX2 231 Y
LBX1 10 102986733 102988717 102886733 103088717 LBX1 169
FGF8 10 103529887 103535827 103429887 103635827 FGF8 43
MYOD1 11 17741110 17743678 17641110 17843678 MYOD1 174
PAX6 11 31806340 31839509 31706340 31939509 PAX6 151 Y
MYF5 12 81110708 81113447 81010708 81213447 MYF5 135
TBX5 12 114791735 114846247 114691735 114946247 TBX5 281 Y Y
DACH1 13 72012098 72441330 71912098 72541330 DACH1 641 Y Y
SLC22A17 14 23815527 23822080 23715527 23922080 SLC22A17 182 Y Y
COCH 14 31343741 31359822 31243741 31459822 COCH 256 Y Y
OTX2 14 57267425 57277184 57167425 57377184 OTX2 246 Y
SIX6 14 60975938 60978525 60875938 61078525 SIX614 531 Y
SIX1 14 61111417 61116155 61011417 61216155 SIX614
SIX4 14 61176256 61190792 61076256 61290792 SIX614
SALL1 16 51169886 51185183 51069886 51285183 SALL1 207 Y
GOSR2 17 45000486 45018733 44900486 45118733 GOSR2 128 Y
SIX5 19 46268044 46272312 46168044 46372312 SIX5 173
PAX1 20 21686297 21696620 21586297 21796620 PAX1 151 Y
EYA2 20 45523509 45817492 45423509 45917492 EYA2 413 Y
Total 38 35 9817 15 16
Chr, chromosome; ROI, region of interest.
* Using NCBI build 36.3.
† Y  nominally significant for trait (for 1 or more SNPs P  0.05) in the RS-I (our discovery cohort).
SALLI and SIX1 previously found to be genome-wide significantly associated with DA and VCDR.
TABLE 2. General Characteristics of the Four Study Populations
RS-I RS-II RS-III ERF
Total sample size (N) 5312 2048 1966 1919
Age, y 68.0  8.4 (55–99) 64.3  7.8 (55–98) 55.6  5.5 (45–89) 47.0  14.0 (18–85)
Gender, female, n (%) 3099 (58.3) 1109 (54.2) 1102 (56.1) 1081 (56.3)
Disc area, mm2* 2.42  0.48 (0.58–5.44) 2.32  0.48 (1.06–6.20) 1.92  0.45 (0.70–7.20) 1.91  0.35 (1.07–4.33)
VCDR* 0.50  0.14 (0.00–0.89) 0.50  0.14 (0.00–0.87) 0.42  0.17 (0.00–1.00) 0.46  0.15 (0.00–0.84)
Data are presented as mean  standard deviation (range) unless stated otherwise.
* In RS-I and RS-II measured with stereoscopic images; in RS-III and ERF with confocal scanning laser ophthalmoscopy.
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forming a more stringent multiple testing adjustment only the
PAX6 region remains significant (p-sig  5.20  106).
Though the SNPs for PAX6 were not significant in ERF, the
direction of the effect was the same as in the other three
cohorts.
Figure 1 shows regional plots of the three candidate genes
using the P values of RS-I only, as this cohort is the only one in
which we investigated all SNPs. The three top SNPs for PAX6
(rs7126851, rs7104512, and rs10835818) were located 57 kb
to 96 kb 3 of PAX6 in its neighboring gene ELP4 (Fig. 1A). The
top SNP (rs2064773) for PAX1 was located 85 kb from the 3
end of the gene with no genes in between the top SNP and the
gene of interest (Fig. 1B). Also for SIX2 (Fig. 1C) no genes
could be found between the top SNP and the gene of interest.
The top SNP (rs2280220) for SIX2was located only 13 kb from
the 5 end of the gene.
DISCUSSION
We found three genes to be associated with DA: PAX6, PAX1,
and SIX2. When adjusting for the number of SNPs sent for
replication, one gene (PAX6) survived the most stringent Bon-
ferroni correction on all SNPs tested in this study. None of the
selected candidate genes could be associated with VCDR.
The protein products of PAX6 and PAX1 are among 25
proteins listed in the internet databases (GeneCards; www.gene
cards.org) which interact with SIX1. The PAX family of genes is a
group of highly conserved developmental control genes encoding
nuclear transcription factors, regulating the expression of other
genes, which have been shown to play a role in organogenesis.
Our only significant finding after adjustment for multiple testing
concerns PAX6 (three SNPs with P values to the order of 106).
Pax6 has been shown to function in the genetic control of eye
development in organisms ranging from planarians to humans.15
In both insects and vertebrates, Pax6 is expressed in the embryo
just before and during formation of the eye in the region of its
development.16 For eye morphogenesis in insects and verte-
brates, the Pax6 paired domain seems to be paramount.17 The
Drosophila Pax6 homologue is the eyeless gene (ey).18 In mice
Pax6 causes Small eye (sey); in humans PAX6 is associated with
aniridia, Peter’s anomaly and other types of anterior segment
dysgenesis.19–21 Clinically, aniridia has frequently been associated
with glaucoma; more than half of aniridic patients will develop
glaucoma.22,23 A mutation in one allele is sufficient to cause
ocular defects through haploinsufficiency, while compound
heterozygosity is usually lethal and includes defects in the brain
and other organs.21,24 PAX6 has tissuemaintenance functions and
continues to be expressed in the adult eye, leading investigators
to speculate that PAX6 may possibly play a role in adult-onset
POAG and/or age-related macular degeneration.5,24 The three
SNPs that were found to be significantly associatedwith DA in this
study were located downstream of the PAX6 gene within an
intronic region of neighboring ELP4. PAX6 is one of many genes
listed in the internet databases (GeneCards; www.
genecards.org) which interact with ELP4. Possibly ELP4 has a
role in regulating PAX6.25,26 The ELP4 gene encodes a com-
ponent of the six subunit elongator complex, a histone acetyl-
transferase complex that associates directly with the RNA poly-
merase II (Pol II) holoenzyme, and is involved in transcriptional
elongation. Elongator may play a role in chromatin remodeling
and is involved in acetylation of histones H3 and probably H4.
Some familial aniridia cases have an undamaged PAX6 gene but
a deletion in the region 3 to it at the level of the ELP4 gene;
microdeletions 3 of PAX6 have been known to suppress
expression of PAX6 and cause aniridia.25–27 Perhaps new tech-
niques like Next Generation Sequencing will be able to dis-
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FIGURE 1. Regional plots of the
three loci found to be associated
with optic disc area in the meta-anal-
ysis with our four cohorts for PAX6
(A), PAX1 (B) and SIX2 (C).
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Although not significant after adjusting for multiple testing
like PAX6, PAX1 also plays a role in the development of the
central nervous system. In mice Pax1 is known to be ex-
pressed in segmented structures during embryogenesis. The
mouse Pax1 mutant phenotype undulated, caused by a mis-
sense mutation in the paired box of Pax1, shows segmentation
anomalies along the entire axial skeleton and defects in the
pectoral girdle.28 By phenotypic similarity, human PAX1 has
been postulated as a candidate gene for Klippel-Feil syndrome,
characterized by failed segmentation of the cervical vertebrae
and other vertebral anomalies.28 However, this association is
inconclusive.28,29 Interesting to note is that in human PAX1
the protein product contains additional amino acids upstream
of the paired box, while in PAX6 the protein sequences are
identical between mice and humans.24,28 As of yet, the litera-
ture on PAX1 is limited. As pointed out by several authors,
many members of the eye developmental cascade of transcrip-
tion factors, including PAX6, also play a role in the genesis of
other tissues.17,24 Further research may reveal more about the
nature of the association between PAX1 and DA.
SIX2, which interacts with SALL1, is a member of the
Drosophila sine oculis homeobox homologues and encodes a
transcription factor associated with organ development. Also
this finding is not significant after adjusting for multiple testing
but is of interest. The Six proteins are part of the Pax/Eya/Six/
Dach retinal determination cascade involved in embryonic cell
fate determination.30 As are a number of other genes in the
Pax/Eya/Six network, Six2 is expressed in the mesenchyme
and plays an important role in early kidney development as
well as in eye and muscle formation in mammals.31 In mam-
mals and humans, Six2 has been associated with renal hypopla-
sia,32 suggesting a role in regulating mesenchymal progenitor
cells,33 frontonasal dysplasia34 and anterior cranial base de-
fects.35 In mouse studies, Six2 transcripts have been found in
a variety of nonneuronal connective tissues, including the eye,
during organogenesis.36
Other candidate genes in the network, for example SIX3
and PAX2, did not interact with PAX617. This may in part be
explained by a lack of statistical power. Larger numbers will be
needed to determine whether these genes are associated with
DA or not. More generally, one would expect that more of the
genes that interact in the pathways of the PAX regulatory
network, such as the SIX and EYA (eyes absent homolog)
families, known to play a role in oculogenesis in Drosophila,
would be significantly associated with either DA or VCDR.
Obviously, these transcription factors play multiple roles in
complex pathways involved not specifically or exclusively in
the eye but more broadly in the central nervous system and in
sensory neurogenesis, affecting the development of multiple
organ systems. Many of these genes are highly conserved and
serve multiple functions within a complex network of interde-
pendencies and feedback loops. The individual effect of a gene
on human optic nerve tissue may be subtle, absent, or subject
to dosage effects. We may not have sufficient statistical power
to detect these by association with either DA or VCDR in our
populations. Further research is needed to tease out any of the
possible roles these genes may play in the formation of the
optic nerve head or optic disc cupping, or more generally in
ocular pathology; at present these roles remain somewhat
speculative.
While none of our SNPs reached genome-wide significance,
the PAX6/ELP4 region remained significant after adjusting for
multiple testing. When we attempted to corroborate the asso-
ciations we found with DA in the ERF cohort we found that,
although not significant, the direction of the effect for the SNPs
in PAX6 was the same as in the other three cohorts. Further
research in a larger sample is required to validate the associa-
tion between PAX6/ELP4 and DA.
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